Decera Clinical Education Oncology Podcast

In this podcast episode, Neeraj Agarwal, MD, FASCO, and Emmanuel S. Antonarakis, MD, discuss the evolving role of PARP inhibitors in metastatic prostate cancer, emphasizing early molecular testing to identify appropriate patients for PARP-directed therapy and proactive adverse event management to support treatment continuation, including:

• HRR alterations and the mechanism of action of PARP inhibitors
• Germline and somatic genomic testing and practical considerations for tissue and ctDNA testing
• PARP inhibitor monotherapy and combination strategies, including data from AMPLITUDE and TALAPRO-3
• Treatment selection across metastatic prostate cancer settings based on HRR alterations
• PARP inhibitor toxicity management, with emphasis on anemia, gastrointestinal effects, monitoring, and dose modification

Presenters:

Neeraj Agarwal, MD, FASCO
Medical Oncologist, Dana-Farber Cancer Institute
Co-Director, Prostate Cancer Program, Harvard Cancer Consortium
The Lank Center for Genitourinary Oncology
Boston, Massachusetts

Emmanuel S. Antonarakis, MD
Clark Endowed Professor of Medicine
Director of GU Oncology, Associate Director of Translation
Division of Hematology, Oncology and Transplantation
University of Minnesota, Masonic Cancer Center
Minneapolis, Minnesota

Link to full program: 
https://bit.ly/4dtT35U

Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Listen to Jesus G. Berdeja, MD, and Ajai Chari, MD, as they discuss sequencing of antibody–drug conjugates (ADCs), bispecific antibodies, CAR T-cell therapy, and other novel treatment modalities for patients with relapsed/refractory multiple myeloma.

Presenters:
Jesus G. Berdeja, MD
Director of Myeloma Research
Greco-Hainsworth Centers for Research 
Partner
Tennessee Oncology
Nashville, Tennessee

Ajai Chari, MD
Professor of Clinical Medicine
Director of Multiple Myeloma Program
UCSF Helen Diller Family Comprehensive Cancer Center
University of California, San Francisco (UCSF) Medical Center
San Francisco, California

Content based on an online CME program supported by an educational grant from GSK.

Link to full program:
https://bit.ly/3TZSmuf

Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode, Hope S. Rugo, MD, FASCO, and Nerea Lopetegui-Lia, MD, discuss practice-informing data presented at ASCO 2026 for patients with metastatic breast cancer, including:

• Findings from SERENA-6 on ctDNA-guided treatment switching for emergent ESR1 mutations before radiographic progression, including updated PFS2 and downstream treatment outcomes
• Emerging precision strategies in HR-positive/HER2-negative advanced breast cancer from ELEVATE and PIKALO-1, including elacestrant plus capivasertib and mutant-selective PI3Kα inhibition with tersolisib
• First-line TROP2-directed ADC data from ASCENT-04, ASCENT-03, and TROPION-Breast02, with discussion of PFS2, subsequent therapy, immunotherapy eligibility, and treatment sequencing

Presenters: 
Hope S. Rugo, MD, FASCO  
Director, Women’s Cancer Program 
Division Chief, Breast Medical Oncology 
Professor, Department of Medical Oncology & Therapeutics Research 
City of Hope Comprehensive Cancer Center 
Professor Emeritus and Emeritus Winterhof Family Distinguished Professor of Breast Oncology 
University of California, San Francisco 
San Francisco, California 

Nerea Lopetegui-Lia, MD 
Assistant Professor 
Division of Medical Oncology, Breast Section 
Department of Internal Medicine 
The Ohio State University 
Columbus, Ohio 

Get access to all of our new podcasts by subscribing to the Decera Clinical Education [Oncology] Podcast on Apple Podcasts, YouTube Music, or Spotify.

Link to full program:
https://bit.ly/4x4u5AT

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode, Charles Rudin, MD, PhD, and Mark A. Socinski, MD, discuss current gaps and clinical needs for patients with relapsed ES-SCLC, and the evolving role of B7-H3–directed antibody–drug conjugates in the management of patients with ES-SCLC, including:

• Clinical needs for relapsed ES-SCLC
• Scientific rationale for targeting B7-H3 and other tumor-associated antigens in SCLC
• ADCs, T-cell engagers, chemotherapy-based approaches, maintenance strategies, and ongoing clinical trials for ES-SCLC
• Recent efficacy and safety data for B7-H3–directed ADCs in ES-SCLC, including I-DXd
• Personalization of care of patients with SCLC, including patient-specific factors influencing treatment
• Case discussion of a patient with ES-SCLC requiring optimal next best treatment
• Importance of enrolling patients in ongoing trials of investigational agents for patients with ES-SCLC

Presenters:
Charles Rudin, MD, PhD
Cancer Center Director
Memorial Sloan Kettering Cancer Center
New York, New York

Mark A. Socinski, MD
Executive Medical Director
AdventHealth Cancer Institute
Orlando, Florida

Link to full program:
https://bit.ly/3UBEeYz

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode, BJ Rimel, MD, and Elizabeth Lee, MD, discuss the scientific rationale for targeting CDH6 in ovarian cancer and the emerging role of CDH6-directed antibody–drug conjugates (ADCs) in platinum-resistant disease, including:

• CDH6 biology, expression patterns, and its potential as a therapeutic target in ovarian cancer
• Early-phase efficacy data with investigational CDH6-directed ADCs, including raludotatug deruxtecan (R-DXd) and CUSP06, and an ongoing phase III trial of R-DXd
• Safety considerations with CDH6-directed ADCs, including cytopenias, gastrointestinal toxicities, fatigue, and interstitial lung disease/pneumonitis
• Considerations for sequencing ADCs, including the potential impact of target expression, payload class, and mechanisms of resistance

Presenters:

BJ Rimel, MD
Division Chief, Gynecologic Oncology
Professor, Department of OB/GYN
University of Washington
Clinical Director of Gynecologic Oncology
Fred Hutchinson Cancer Center
Seattle, Washington

Elizabeth Lee, MD
Division of Gynecologic Oncology
Center for Cancer Therapeutic Innovation
Department of Medical Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts

Link to full program: 
https://bit.ly/3SqCAZ6

Get access to all of our new podcasts by subscribing to the Decera Clinical Education Podcast on Apple Podcasts, YouTube Music, or Spotify.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode, Hope S. Rugo, MD, FASCO, and Nerea Lopetegui-Lia, MD, discuss practice-informing data presented at ASCO 2026 for patients with early-stage hormone receptor (HR)–positive/HER2-negative breast cancer, including:

• Findings from the OPTIMA trial evaluating Prosigna gene expression testing to guide adjuvant chemotherapy decisions in patients with high-risk HR-positive/HER2-negative early breast cancer
• The importance of ovarian function suppression plus endocrine therapy when considering chemotherapy-sparing strategies in premenopausal patients
• Results from the NATALEE PAM50 biomarker analysis, showing ribociclib benefit across intrinsic subtypes with no significant treatment-by-subtype interaction

Presenters:

Hope S. Rugo, MD, FASCO
Director, Women’s Cancer Program
Division Chief, Breast Medical Oncology
Professor, Department of Medical Oncology & Therapeutics Research
City of Hope Comprehensive Cancer Center
Professor Emeritus and Emeritus Winterhof Family Distinguished Professor of Breast Oncology
University of California, San Francisco
San Francisco, California

Nerea Lopetegui-Lia, MD
Assistant Professor
Division of Medical Oncology, Breast Section
Department of Internal Medicine
The Ohio State University
Columbus, Ohio

Get access to all of our new podcasts by subscribing to the Decera Clinical Education [Oncology] Podcast on Apple Podcasts, YouTube Music, or Spotify.

Link to full program: 
https://bit.ly/4x4u5AT

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Treatment options for patients with lymphoma are rapidly evolving. In this podcast episode, Alex F. Herrera, MD, and Marc Hoffmann, MD, discuss cereblon E3 ligase modulators (CELMoDs) as potential treatment options for patients with aggressive diffuse large B-cell lymphoma and follicular lymphoma, with a focus on golcadomide, an investigational, oral, first-in-class CELMoD therapy. Topic areas covered include: 

Presenters:

Alex F. Herrera, MD

Marc Hoffmann, MD

Content based on an online CME program supported by an educational grant from Bristol Myers Squibb.

Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify.

Link to CME: Claim Credit

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode, Jesus G. Berdeja, MD, and Ajai Chari, MD, discuss health disparities and equitable care strategies in multiple myeloma, including:

Presenters:
Jesus G. Berdeja, MD

Ajai Chari, MD

Content based on an online CME program supported by an educational grant from GSK.

Link to full program:
https://bit.ly/3TZSmuf

Get access to all of our new podcasts by subscribing tothe Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode, Meletios-Athanasios (Thanos) C. Dimopoulos, MD, and María-Victoria Mateos, MD, PhD, as they discuss the use of CELMoD agents to manage multiple myeloma, including: 

Presenters:
Meletios-Athanasios (Thanos) C. Dimopoulos, MD

María-Victoria Mateos, MD, PhD

Content based on an online CME program supported by an educational grant from Bristol Myers Squibb.

Link to full program:
https://bit.ly/4xgnHri

Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Danielle Roman, PharmD, BCOP, and Jordan Hill, PharmD, BCOP, discuss optimal care for patients with HR-positive/HER2-negative breast cancer receiving newer oral targeted therapies. Their conversation addresses treatment selection across early-stage and metastatic disease, biomarker-informed decision-making, adverse event management, and practical strategies to help patients remain on therapy.

Key topics include:

Presenters
Danielle Roman, PharmD, BCOP

Jordan Hill, PharmD, BCOP

Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Access the full educational program:

Link to full program:
https://bit.ly/4gvZerW

And be sure to try our Interactive Decision Support Tools for Early Breast Cancer and Selecting AKT or PI3K Inhibitors for Patients With Metastatic Breast Cancer. By answering just a few quick questions, you can see what 5 experts would recommend for specific patient scenarios.

Early Breast Cancer:
https://bit.ly/4gtUiUq

AKT or PI3K Inhibitors in MBC:
https://bit.ly/4qcyBvk

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.